MiRNA-146b-5p upregulates migration and invasion of different Papillary Thyroid Carcinoma cells

BMC Cancer

Volumn 16, Issue 1, 2016, Pages

  Lima, Cilene Rebouças ^a   Geraldo, Murilo Vieira ^a   Fuziwara, Cesar Seigi ^a   Kimura, Edna Teruko ^a   Santos, Marinilce Fagundes ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Cancer; Cell migration; Invasion; MicroRNAs; MiR 146b; PTC; Thyroid

Indexed keywords

MICRORNA; MICRORNA 146B; MICRORNA 146B 5P; SMAD4 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL INVASION; CELL MIGRATION; CELL POLARITY; CONTROLLED STUDY; GENE FUNCTION; GENE IDENTIFICATION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; NONHUMAN; PAPILLARY THYROID CARCINOMA CELL; RAT; UPREGULATION; ANIMAL; CARCINOMA; CELL LINE; CELL MOTION; DRUG EFFECTS; GENETIC TRANSFECTION; GENETICS; METABOLISM; THYROID TUMOR; TUMOR CELL LINE; TUMOR INVASION;

ANIMALS; CARCINOMA; CELL LINE; CELL LINE, TUMOR; CELL MOVEMENT; MICRORNAS; NEOPLASM INVASIVENESS; RATS; THYROID NEOPLASMS; TRANSFECTION; UP-REGULATION;

EID: 84957945122     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-016-2146-z     Document Type: Article

References (49)

1. Potter DP. Morphogens, morphostats, microarchitecture and malignancy. Nat Rev Cancer. 2007;7:464-74.
2. Welf ES, Haugh JM. Signaling pathways that control cell migration: models and analysis. Wiley Interdiscip Rev Syst Biol Med. 2011;3:231-40.
3. Parsons JT, Horwitz AR, Schwartz MA. Cell adhesion: integrating cytoskeletal dynamics and cellular tension. Nat Rev Mol Cell Biol. 2010;11:633-43. doi: 10.1038/nrm2957.
4. Thumkeo D, Watanabe S, Narumiya S. Physiological roles of Rho and Rho effectors in mammals. Eur J Cell Biol. 2013;92:303-15. doi: 10.1016/j.ejcb.2013.09.002.
5. Liu M, Bi F, Zhou X, Zheng Y. Rho GTPase regulation by miRNAs and covalent modifications. Trends Cell Biol. 2012;22:365-73. doi: 10.1016/j.tcb.2012.04.004.
6. Lee YS, Dutta A. MicroRNAs in Cancer. Annu Rev Pathol Mech Dis. 2009;4:199-227.
7. White NM, Fatoohi E, Metias M, Jung K, Stephan C, Yousef GM. Metastamirs: a stepping stone towards improved cancer management. Nat Rev Clin Oncol. 2011;8:75-84. doi: 10.1038/nrclinonc.2010.173.
8. Fuziwara CS, Kimura ET. MicroRNA Deregulation in Anaplastic Thyroid Cancer Biology. Int J Endocrinol. 2014;743450. doi: 10.1155/2014/743450
9. Sipos JA, Mazzaferri EL. Thyroid cancer epidemiology and prognostic variables. Clin Oncol (R Coll Radiol). 2010;22:395-404. doi: 10.1016/j.clon.2010.05.004.
10. Loh KC, Greenspan FS, Gee L, Miller TR, Yeo PP. Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients. J Clin Endocrinol Metab. 1997;82:3553-62.
11. Brito JP, Hay ID, Morris JC. Low risk papillary thyroid cancer. BMJ. 2014;348:g3045. doi: 10.1136/bmj.g3045. Review.
12. Torre LA, Siegel RL, Ward EM, Jemal A. Global Cancer Incidence and Mortality Rates and Trends-An Update. Cancer Epidemiol Biomarkers Prev. 2016;25:16-27.
13. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA. Carcinoma RET/PTC-RAS-BRAF Signaling Pathway in Papillary Thyroid Genetic Evidence for Constitutive Activation of the High Prevalence of BRAF Mutations in Thyroid Cancer. Cancer Res. 2003;63(7):1454-7.
14. Matsuo SE, Leoni SG, Colquhoun A, Kimura ET. Transforming growth factor-beta1 and activin A generate antiproliferative signaling in thyroid cancer cells. J Endocrinol. 2006;190:141-50.
15. Kimura ET, Matsuo SE, Ricarte-Filho JC. TGFbeta, activin and SMAD signalling in thyroid cancer. Arq Bras Endocrinol Metabol. 2007;51:683-9.
16. He H, Jazdzewski K, Li W, Liyanarachchi S, Nagy R, Volinia S, et al. The role of microRNA genes in papillary thyroid carcinoma. Proc Natl Acad Sci U S A. 2005;102:19075-80.
17. Pallante P, Visone R, Ferracin M, Ferraro A, Berlingieri MT, Troncone G, et al. MicroRNA deregulation in human thyroid papillary carcinomas. Endocr Relat Cancer. 2006;13:497-508.
18. Nikiforova MN, Tseng GC, Steward D, Diorio D, Nikiforov YE. MicroRNA expression profiling of thyroid tumors: biological significance and diagnostic utility. J Clin Endocrin Metab. 2008;49:1-17.
19. Nikiforova MN, Chiosea SI, Nikiforov YE. MicroRNA Expression Profiles in Thyroid Tumors. Endocr Pathol. 2009;20:85-91.
20. Schwertheim S, Sheu SY, Worm K, Grabellus F, Schmid KW. Analysis of deregulated miRNAs is helpful to distinguish poorly differentiated thyroid carcinoma from papillary thyroid carcinoma. Horm Metab Res. 2009;41:475-81. doi: 10.1055/s-0029-1215593.
21. Sheu SY, Grabellus F, Schwertheim S, Worm K, Broecker-Preuss M, Schmid KW. Differential miRNA expression profiles in variants of papillary thyroid carcinoma and encapsulated follicular thyroid tumours. Br J Cancer. 2010;102:376-82.
22. Zhou YL, Liu C, Dai XX, Zhang XH, Wang OC. Overexpression of miR-221 is associated with aggressive clinicopathologic characteristics and the BRAF mutation in papillary thyroid carcinomas. Med Oncol. 2012;29:3360-6.
23. Pallante P, Battista S, Pierantoni GM, Fusco A. Deregulation of microRNA expression in thyroid neoplasias. Nat Rev Endocrinol. 2014;10:88-101.
24. Chou CK, Chen RF, Chou FF, Chang HW, Chen YJ, Lee YF, et al. miR-146b is highly expressed in adult papillary thyroid carcinomas with high risk features including extrathyroidal invasion and the brafv600e mutation. Thyroid. 2010;20:489-94.
25. Yip L, Kelly L, Shuai Y, Armstrong MJ, Nikiforov YE, Carty SE, et al. MicroRNA signature distinguishes the degree of aggressiveness of papillary thyroid carcinoma. Ann Surg Oncol. 2011;18:2035-41.
26. Wang Z, Zhang H, He L, Dong W, Li J, Shan Z, et al. Association between the expression of four upregulated miRNAs and extrathyroidal invasion in papillary thyroid carcinoma. Onco Targets Ther. 2013;6:281-7.
27. Geraldo MV, Fuziwara CS, Friguglieti CU, Costa RB, Kulcsar MA, Yamashita AS, et al. MicroRNAs miR-146-5p and let-7f as prognostic tools for aggressive papillary thyroid carcinoma: a case report. Arq Bras Endocrinol Metabol. 2012;56:552-7.
28. Chou CK, Yang KD, Chou FF, Huang CC, Lan YW, Lee YF, et al. Prognostic Implications of miR-146b Expression and Its Functional Role in Papillary Thyroid Carcinoma. J Clin Endocrinol Metab. 2013;98:E196-205.
29. Ishizaka Y, Ushijima T, Sugimura T, Nagao M. cDNA cloning and characterization of ret activated in a human papillary thyroid carcinoma cell line. Biochem Biophys Res Commun. 1990;168:402-8.
30. Fabien N, Fusco A, Santoro M, Barbier Y, Dubois PM, Paulin C. Description of a human papillary thyroid carcinoma cell line. Morphologic study and expression of tumoral markers. Cancer. 1994;73:2206-12.
31. Geraldo MV, Yamashita AS, Kimura ET. MicroRNA miR-146b-5p regulates signal transduction of TGF-b by repressing SMAD4 in thyroid cancer. Oncogene. 2012;31:1910-22.
32. Xia H, Qi Y, Ng SS, Chen X, Li D, Chen S, et al. microRNA-146b inhibits glioma cell migration and invasion by targeting MMPs. Brain Res. 2009;1269:158-65. doi: 10.1016/j.brainres.2009.02.037.
33. Katakowski M, Zheng X, Jiang F, Rogers T, Szalad A, Chopp M. MiR-146b-5p suppresses EGFR expression and reduces in vitro migration and invasion of glioma. Cancer Invest. 2010;28:1024-30. doi: 10.3109/07357907.2010.512596.
34. Patnaik SK, Kannisto E, Mallick R, Yendamuri S. Overexpression of the lung cancer-prognostic miR-146b microRNAs has a minimal and negative effect on the malignant phenotype of A549 lung cancer cells. PLoS One. 2011;6, e22379. doi: 10.1371/journal.pone.0022379.
35. Lin F, Wang X, Jie Z, Hong X, Li X, Wang M, et al. Inhibitory effects of miR-146b-5p on cell migration and invasion of pancreatic cancer by targeting MMP16. J Huazhong Univ Sci Technolog Med Sci. 2011;31:509-14. doi: 10.1007/s11596-011-0481-5.
36. Al-Khalaf HH, Aboussekhra A. MicroRNA-141 and MicroRNA-146b-5p Inhibit the Prometastatic Mesenchymal Characteristics through the RNA-binding Protein AUF1 Targeting the Transcription Factor ZEB1 and the Protein Kinase AKT. J Biol Chem. 2014;289:31433-47. doi: 10.1074/jbc.M114.593004.
37. Li Y, Wang Y, Yu L, Sun C, Cheng D, Yu S, et al. miR-146b-5p inhibits glioma migration and invasion by targeting MMP16. Cancer Lett. 2013;339:260-9. doi: 10.1016/j.canlet.2013.06.018.
38. Yang Z, Yuan Z, Fan Y, Deng X, Zheng Q. Integrated analyses of microRNA and mRNA expression profiles in aggressive papillary thyroid carcinoma. Mol Med Rep. 2013;8:1353-8. doi: 10.3892/mmr.2013.1699.
39. Deng X, Wu B, Xiao K, Kang J, Xie J, Zhang X, et al. MiR-146b-5p promotes metastasis and induces epithelial-mesenchymal transition in thyroid cancer by targeting ZNRF3. Cell Physiol Biochem. 2015;35:71-82. doi: 10.1159/000369676.
40. Wojtas B, Ferraz C, Stokowy T, Hauptmann S, Lange D, Dralle H, et al. Differential miRNA expression defines migration and reduced apoptosis in follicular thyroid carcinomas. Mol Cell Endocrinol. 2014;388:1-9. doi: 10.1016/j.mce.2014.02.011.
41. Sancho M, Vieira JM, Casalou C, Mesquita M, Pereira T, Cavaco BM, et al. Expression and function of the chemokine receptor CCR7 in thyroid carcinomas. J Endocrinol. 2006;191:229-38. doi: 10.1677/joe.1.06688.
42. Scarpino S, Di Napoli A, Melotti F, Talerico C, Cancrini A, Ruco L. Papillary carcinoma of the thyroid: low expression of NCAM (CD56) is associated with downregulation of VEGF-D production by tumour cells. J Pathol. 2007;212:411-9. doi: 10.1002/path.2183.
43. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell. 2009;139:871-90. doi: 10.1016/j.cell.2009.11.007.
44. Mincione G, Di Marcantonio MC, Tarantelli C, D'Inzeo S, Nicolussi A, Nardi F et al. EGF and TGF-β1 Effects on Thyroid Function. J Thyroid Res. 2011;431718. doi: 10.4061/2011/431718
45. Massagué J. TGFbeta in Cancer. Cell. 2008;134:215-30. doi: 10.1016/j.cell.2008.07.001.
46. Takaku K, Oshima M, Miyoshi H, Matsui M, Seldin MF, Taketo MM. Intestinal tumorigenesis in compound mutant mice of both Dpc4 (Smad4) and Apc genes. Cell. 1998;92:645-56. doi: 10.1016/S0092-8674(00)81132-0.
47. D'Inzeo S, Nicolussi A, Ricci A, Mancini P, Porcellini A, Nardi F, et al. Role of reduced expression of SMAD4 in papillary thyroid carcinoma. J Mol Endocrinol. 2010;45:229-44. doi: 10.1677/JME-10-0044.
48. Papageorgis P, Cheng K, Ozturk S, Gong Y, Lambert AW, Abdolmaleky HM, et al. Smad4 inactivation promotes malignancy and drug resistance of colon cancer. Cancer Res. 2011;71(3):998-1008.
49. Morgenstern JP, Land H. Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. Nucleic Acids Res. 1990;18(12):3587-96.